International Stem Cell (ISCO) Asset Utilization Ratio (2011 - 2026)
International Stem Cell (ISCO) posted quarterly Asset Utilization Ratio of 1.8 for Q4 2025, up 2.66% year-over-year from 1.76 in Q4 2024, and up 3.89% quarter-over-quarter from 1.73 in Q3 2025.
International Stem Cell (ISCO) Asset Utilization Ratio (2011 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Asset Utilization Ratio for 15 consecutive years, with 1.8 the latest figure, recorded in Q4 2025.
- In Q4 2025, Asset Utilization Ratio rose 2.66% year-over-year to 1.8; the TTM figure through Dec 2025 stood at 1.8 (up 2.66% YoY), while the FY2025 annual figure was 1.82, up 5.89% from the prior year.
- Asset Utilization Ratio rose to 1.8 in Q4 2025 per ISCO's latest filing, from 1.73 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 1.8 in Q4 2025 and bottomed at 1.11 in Q2 2021.
- Historically, Asset Utilization Ratio has averaged 1.5 across 5 years, with a median of 1.46 in 2023.
- Annual changes were most pronounced in 2021 — Asset Utilization Ratio decreased 20.2% — and 2022, when it grew 27.74%.
- International Stem Cell's Asset Utilization Ratio stood at 1.45 in 2021, then advanced by 10.7% to 1.61 in 2022, then declined by 12.15% to 1.41 in 2023, then increased by 24.28% to 1.76 in 2024, then increased by 2.66% to 1.8 in 2025.
- Business Quant data shows ISCO's Asset Utilization Ratio at 1.8 in Q4 2025, 1.73 in Q3 2025, and 1.65 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 0.90 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.54 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.13 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.13 |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 1.95 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.95 |
| Dec 31, 2025 | 1.80 |
| Sep 30, 2025 | 1.73 |
| Jun 30, 2025 | 1.65 |
| Mar 31, 2025 | 1.68 |
| Dec 31, 2024 | 1.76 |
| Sep 30, 2024 | 1.58 |
| Jun 30, 2024 | 1.52 |
| Mar 31, 2024 | 1.46 |
| Dec 31, 2023 | 1.41 |
| Sep 30, 2023 | 1.46 |
| Jun 30, 2023 | 1.45 |
| Mar 31, 2023 | 1.57 |
| Dec 31, 2022 | 1.61 |
| Sep 30, 2022 | 1.45 |
| Jun 30, 2022 | 1.42 |
| Mar 31, 2022 | 1.44 |
| Dec 31, 2021 | 1.45 |
| Sep 30, 2021 | 1.29 |
| Jun 30, 2021 | 1.11 |